AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|
27.3 C
New York
Wednesday, July 29, 2026

Tag: development program

newssourceFORcompanyinformationcontent1releasesmarket

Andrius Kavaliauskas to replace UAB “Ignitis” CEO Artūras Bortkevičius after the end of his term  

The Board of UAB “Ignitis”, a subsidiary directly controlled by Ignitis Group, a leading integrated energy group in the Baltic region (hereinafter – the Group), has approved the candidacy of Andrius Kavaliauskas for the position of CEO of UAB “Ignitis”. Andrius Kavaliauskas, the current Head of B2C at the company, will replace the company's CEO Artūras Bortkevičius, whose term of office expires on 9 July 2026. The final decision on the appointment of Andrius Kavaliauskas to the position of CEO of UAB “Ignitis” is planned to be made by 9 July 2026, following the completion of the mandatory impeccable reputation verification procedure.

Andrius Kavaliauskas to replace UAB “Ignitis” CEO Artūras Bortkevičius after the end of his term

The Board of UAB “Ignitis”, a subsidiary directly controlled by Ignitis Group, a leading integrated energy group in the Baltic region (hereinafter – the Group), has approved the candidacy of Andrius Kavaliauskas for the position of CEO of UAB “Ignitis”. Andrius Kavaliauskas, the current Head of B2C at the company, will replace the company's CEO Artūras Bortkevičius, whose term of office expires on 9 July 2026. The final decision on the appointment of Andrius Kavaliauskas to the position of CEO of UAB “Ignitis” is planned to be made by 9 July 2026, following the completion of the mandatory impeccable reputation verification procedure.

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

Immunic to Participate in Investor, Industry and Scientific Conferences in June

NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...

Humboldt Seed Company and Marley Family Launch Two New Cannabis Seed Strains

Globally recognized cannabis brand honors Bob Marley with release of Redemption and One Love cannabis seeds.SAN FRANCISCO, June 9, 2026 /PRNewswire/ -- Humboldt Seed...

Exilby® Receives First European Marketing Authorization as VERTANICAL Prepares UK Submission for its First-in-Class Non-Opioid Treatment for Chronic Low Back Pain

GRÄFELFING, Germany, June 9, 2026 /PRNewswire/ -- VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic...

Thea Energy Accelerates Fusion Energy with Helios Power Plant Digital Twin and AI Surrogate Models in Collaboration with NVIDIA, Synopsys, Argonne National Laboratory, and...

The collaboration builds the first digital twin of a stellarator fusion power plant and leverages world leading AI, physics, and engineering for the U.S. Department of Energy’s Genesis Mission

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDevelopment program

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers